Back

Favourable safety profile of S62798, a potent TAFIa (activated thrombin-activatable fibrinolysis inhibitor) inhibitor, in first-in-man study in healthy subjects

31 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Advances in Chronic Thromboembolic Pulmonary Hypertension Clinical ESC Premium Access ESC Congress 2020

About the speaker

Photo
Mrs Florence Petit Dop

International Research Institute Servier (IRIS), Suresnes (France)

2 More presentations in this session

Presentation thumbnail
Accurate and efficient non-invasive strategy for early identification of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism (InShape II study)
Doctor E. Klok (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
De-escalation/discontinuation of oxygen-therapy and medication is feasible and safe in chronic thromboembolic pulmonary hypertension patients treated with balloon pulmonary angioplasty
Doctor M. Kimura (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in Chronic Thromboembolic Pulmonary Hypertension

The Event

Event poster

ESC Congress 2020

31 August 2020 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources